English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives   Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population.Methods   Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-Haenszel method) or a random-effect model (the DerSimonian and Laird method) is used to merge or aggregate the risk ratio (RR) and its 95% confidence intervals (CI) of included studies.Results   Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study. Significant differences (RR = 1.29, 95% CI = 1.20 to 1.40,  P  < 0.001) between patients were observed between the two groups.Conclusions   Our results suggested that the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better than traditional drug treatments.

The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis